An Updated Meta-Analysis of Randomized Controlled Trial Assessing the Effect of Neoadjuvant Chemotherapy in Advanced Gastric Cancer

REFERENCES

• Katherine DC, Alfred IN. Epidemiology of gastric cancer. World J Gastroenterol 2006;12:354–363.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90
   PubMed Web of Science ®Google Scholar
• Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol 2006;12:17–20.
   PubMed Web of Science ®Google Scholar
• Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340, 908–914.
   PubMed Web of Science ®Google Scholar
• Frei E 3rd. Clinical cancer research: an embattled species. Cancer 1982;50:1979–1992.
   PubMed Web of Science ®Google Scholar
• Wilke H, Preusser P, Fink U, Gunzer U, Meyer HJ, Meyer J, Siewert JR, Achterrath W, Lenaz L, Knipp H. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide,doxorubicin, and cisplatin. J Clin Oncol 1989;7:1318–1326
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.
   PubMed Web of Science ®Google Scholar
• Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715–1721.
   PubMed Web of Science ®Google Scholar
• Qu JJ, Shi YR, Liu FR, Ma SQ, Ma FY. A clinical study of paclitaxel combined with FOLFOX4 regimen as neoadjuvant chemotherapy for advanced gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi 2010;13:664–667.
   PubMedGoogle Scholar
• Biffi R, Fazio N, Luca F, Chiappa A, Andreoni B, Zampino MG, Roth A, Schuller JC, Fiori G, Orsi F, Bonomo G, Crosta C, Huber O. Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World J Gastroenterol 2010;16:868–874.
   PubMed Web of Science ®Google Scholar
• Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010;28:5210–5218.
   PubMed Web of Science ®Google Scholar
• Hartgrink HH, van de Velde CJ, Putter H, Songun I, Tesselaar ME, Kranenbarg EK, de Vries JE, Wils JA, van der Bijl J, van Krieken JH. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004;30:643–649.
   PubMed Web of Science ®Google Scholar
• Nio Y, Koike M, Omori H, Hashimoto K, Itakura M, Yano S, Higami T, Maruyama R. A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer–a single institute study. Anticancer Res 2004;24:1879–1887.
   PubMed Web of Science ®Google Scholar
• Wang XL, Wu GX, Zhang MD, Guo M, Zhang H, Sun XF. A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer. Oncol Rep 2000;7:241–244.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Kimura T. Long-term outcome of preoperative chemotherapy with 5′-deoxy-5-fluorouridine (5′-DFUR) for gastric cancer. Gan To Kagaku Ryoho 2000;27:1521–1526.
   PubMedGoogle Scholar
• Lygidakis NJ, Sgourakis G, Aphinives P. Upper abdominal stop-flow perfusion as a neo and adjuvant hypoxic regional chemotherapy for resectable gastric carcinoma. A prospective randomized clinical trial. Hepatogastroenterology 1999;46:2035–2038.
   PubMed Web of Science ®Google Scholar
• Kang YK, Choi DW, Im YH, Kim CM, Lee JI, Moon NM, Lee JO. A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer. Abstract 503 presented at the ASCO Annual Meeting. 1996. Available from:http://www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst_detail_view&confID=29&abstractID= 10042.
   Google Scholar
• Yonemura Y, Sawa T, Kinoshita K, Matsuki N, Fushida S, Tanaka S, Ohoyama S, Takashima T, Kimura H, Kamata T. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 1993;17:256–261; discussion 261–262.
   PubMed Web of Science ®Google Scholar
• Wu AW, Xu GW, Wang HY, Ji JF, Tang JL. Neoadjuvant chemotherapy versus none for resectable gastric cancer. Cochrane Database Syst Rev 2007;18:CD005047.
   Google Scholar
• He LF, Yang KH, Tian JH, Bai ZG. Meta analysis of clinical effectiveness of neoadjuvant chemotherapy for gastric cancer. Ai Zheng 2008;27:407–412.
   PubMedGoogle Scholar
• Li W, Qin J, Sun YH, Liu TS. Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol 2010;16:5621–5628.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.
   PubMedGoogle Scholar
• Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.1 (Updated September 2008). The Cochrane Collaboration 2008. Available from: http://www. cochrane-handbook.org.
   Google Scholar
• Rasanen JV, Sihvo EI, Knuuti MJ, Minn HR, Luostarinen ME, Laippala P, Viljanen T, Salo JA. Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 2003;10(8):954–960.
   PubMed Web of Science ®Google Scholar
• Lowe VJ, Booya F, Fletcher JG, Nathan M, Jensen E, Mullan B, Rohren E,Wiersema MJ, Vazquez-Sequeiros E, Murray JA, Allen MS, Levy MJ, Clain JE. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol 2005;7(6):422–430.
   PubMed Web of Science ®Google Scholar
• Weber WA, Ott K. Imaging of esophageal and gastric cancer. Semin Oncol 2004;31:530–541.
   PubMed Web of Science ®Google Scholar
• Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, Schwaiger M, Fink U. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003;30:288–295.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Yanai H, Tokiyama H, Nishiaki M, Higaki S, Okita K. Endoscopic ultrasonography for diagnosis of submucosal invasion in early gastric cancer. J Gastroenterol 2000;35:326–331.
   PubMed Web of Science ®Google Scholar
• Willis S, Truong S, Gribnitz S, Fass J, Schumpelick V. Endoscopic ultrasonography in the preoperative staging of gastric cancer. Surg Endosc 2000;14:951–954.
   PubMed Web of Science ®Google Scholar
• Polkowski M, Palucki J, Wronska E, Szawlowski A, Nasierowska- Guttmejer A, Butruk E. Endosonography versus helical computed tomography for locoregional staging of gastric cancer. Endoscopy 2004;36:617–623.
   PubMed Web of Science ®Google Scholar
• Meining A, Dittler HJ, Wolf A, Lorenz R, Schusdziarra V, Siewert JR, Classen M, Höfler H, Rösch T. You get what you expect? A critical appraisal of imaging methodology in endosonographic cancer staging. Gut 2002;50:599–603.
   PubMed Web of Science ®Google Scholar
• An JY, Kim HI, Cheong JH, Hyung WJ, Kim CB, Noh SH. Pathologic and oncologic outcomes in locally advanced gastric cancer with neoadjuvant chemotherapy or chemoradiotherapy. Yonsei Med J 2013;4:888–894.
   Google Scholar
• Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Königsrainer A, Budach W, Wilke H. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851–856.
   PubMed Web of Science ®Google Scholar
• Leong T, Smithers M, Michael M, Gebski V, Boussioutas A, Miller D, Zalcberg JR, Wong R, Haustermans K. TOPGEAR: An international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG) [abstract]. J Clin Oncol 2012;30 (suppl): Abstract TPS4141. Available from: http: // abstract.asco.org/AbstView_114_99024.html).
   PubMedGoogle Scholar
• Reim D, Gertler R, Novotny A, Becker K, zum Büschenfelde CM, Ebert M, Dobritz M, Langer R, Hoefler H, Friess H, Schumacher C. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol 2012;19(7):2108–2118.
   PubMed Web of Science ®Google Scholar
• Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Hohenberger P, Jensen K, Kieser M, Slanger TE, GE Adenocarcinoma Meta-analysis Group. Meta-analysis of preoperative chemotherapy (CTX) versus primary surgery for locoregionally advanced adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus (GE adenocarcinoma). J Clin Oncol 2010; 28(Suppl):4022.
   PubMedGoogle Scholar
• Ectors N, Driessen A, De Hertog G, Lerut T, Geboes K. Is adenocarcinoma of the esophagogastric junction or cardia different from Barrett adenocarcinoma? Arch Pathol Lab Med 2005;129:183–185.
   PubMed Web of Science ®Google Scholar
• Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007;17:2–9.
   PubMed Web of Science ®Google Scholar
• Gomes LI, Esteves GH, Carvalho AF, Cristo EB, Hirata R Jr, Martins WK, Marques SM, Camargo LP, Brentani H, Pelosof A, Zitron C, Sallum RA, Montagnini A, Soares FA, Neves EJ, Reis LF. Expression profile of malignant and nonmalignant lesions of esophagus and stomach: differential activity of functional modules related to inflammation and lipid metabolism. Cancer Res 2005; 65:7127–7136.
   PubMed Web of Science ®Google Scholar